The document is an intimation regarding the availability of the audio recording of an Analysts/Investors Earnings Call held by Orchid Pharma Limited.
The event was an earnings call specifically held to discuss the Unaudited Limited Reviewed Financial Results (Standalone and Consolidated) for Quarter-I of Financial Year 2026-27, ended on June 30, 2026.
The call was conducted on August 21, 2026, at 15:00 P.M. (IST) through an Audio Conference call format.
The audio recording has been uploaded to the company's website and is accessible via the provided link: https://orchid-pharma.b-cdn.net/audios/ConcallRecordingQ-1_June30%2C2026.mp3
The company explicitly states that no Video Recording is available for this call.
The disclosure is made pursuant to Regulation 30, Subpara 15 of Para A Part A of Schedule III of the SEBI (LODR) Regulations, 2015, and SEBI Circular no. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
This intimation serves as a continuation to earlier intimations dated August 17 & 20, 2026, regarding the same Analysts/Investors Earnings Call.
Additional Notes Section
The document is signed by Kapil Dayya, Company Secretary & Compliance Officer (Membership No.: F10698).
No financial data, performance figures, or specific management commentary from the call is disclosed in this announcement.
The document contains standard corporate contact information including phone number (+91-124-4848900), email (corporate@orchidpharma.com), website (orchidpharma.com), and registered/corporate office addresses.
